|
|
|
| Effect of Pidotimod combined with recombinant human interferon α1b and Ganciclovir in the treatment of children with EB virus associated infectious mononucleosis#br# |
| ZHANG Hui1 LI Hongyuan2 ZHANG Jianming1▲ |
1.The Second Department of Pediatrics, Fuyang Women and Children’s Hospital, Anhui Province, Fuyang 236000, China;
2.Department of Child Health Care, Fuyang Women and Children’s Hospital, Anhui Province, Fuyang 236000, China |
|
|
|
Abstract Objective To investigate the effect of Pidotimod combined with recombinant human interferon α1b and Ganciclovir in the treatment of children with Epstein-Barr virus (EBV） associated infectious mononucleosis. Methods A total of 80 children with EBV associated infectious mononucleosis admitted to Department of Pediatrics, Fuyang Women and Children’s Hospital, Anhui Province from January 2018 to March 2021 were selected, and they were divided into observation group and control group by random number table method, with 40 cases in each group. Control group was treated with recombinant human interferon α1b and Ganciclovir, and observation group was treated with Pidotimod on the basis of control group, two groups were treated for ten days. Clinical symptoms improved conditions, CD4+, CD8+, CD4+/CD8+, tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin-6 (IL-6), creatine kinase (CK), creatine kinase MB (CK-MB), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) levels were compared, the occurrence of adverse reactions during treatment were recorded. Results The disappearance time of pharyngeal pain, antipyretic time, and relief time of tonsil and lymph node enlargement in observation group were shorter than those in control group, and the differences were statistically significant (P < 0.05). After treatment, CD4+, CD8+, and CD4+/CD8+ in both groups were higher than those before treatment, and observation group was higher than control group, and the differences were statistically significant (P < 0.05). After treatment, the levels of TNF-α, CRP, and IL-6 in two groups were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (P < 0.05). After treatment, the levels of CK, CK-MB, LDH, and AST in two groups were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (P < 0.05). During the treatment, no obvious adverse reactions occurred in two groups. Conclusion Pidomord combined with recombinant human interferon α1b and Ganciclovir in the treatment of children with EBV associated infectious mononucleosis have obvious effect, it’s worthy of promotion and application.
|
|
|
|
|
|
[1] 王华，刘晓东，许超凡，等.儿童传染性单核细胞增多症110例临床分析[J].中国感染与化疗杂志，2019，19（1）：23-26.
[2] 关晓蕾，闫静，赵秋红，等.传染性单核细胞增多症患儿血清抗EB病毒抗体检测结果分析[J].中华实用儿科临床杂志，2021，36（13）：1004-1006.
[3] 王凤圈.更昔洛韦与阿昔洛韦治疗小儿病毒性脑炎临床观察[J].中国实用神经疾病杂志，2019，22（5）：523-528.
[4] 廖亦男，于四景，肖耿吉.转移因子口服液联合更昔洛韦治疗传染性单核细胞增多症的临床效果及对患儿外周血滤泡调节性T细胞表达的影响[J].中国医药，2020，15（11）：1786-1789.
[5] 曹甦，姚惠辉，牛锋.重组人干扰素α-1b雾化治疗婴幼儿疱疹性咽峡炎的临床效果[J].中国医药导报，2019，16（20）：156-158.
[6] 张垚，孙新，张国成.不同剂量重组人干扰素α1b雾化吸入治疗儿童流行性感冒疗效观察[J].海南医学，2020，31（4）：466-469.
[7] 何仁忠，岑敏，王冠，等.玉屏风制剂联合匹多莫德治疗儿童反复呼吸道感染的Meta分析[J].儿科药学杂志，2020， 26（7）：23-27.
[8] 岑敏，赵丹，熊婷，等.匹多莫德对儿童反复呼吸道感染的疗效及免疫功能影响的Meta-分析[J].药物评价研究，2019，42（4）：761-767.
[9] 胡亚美，江载芳，申昆玲，等.诸福棠实用儿科学[M].8版.北京：人民卫生出版社，2015：201-203．
[10] 陈秋雨，韩艳秋.EBV感染相关性疾病的研究现状[J].中华医院感染学杂志，2019，29（7）：1113-1116.
[11] 周雯倩，朱亚非，杨瑜璐.儿童EBV感染与IL-10启动子基因多态性的相关性[J].中华医院感染学杂志，2021， 31（8）：1262-1266.
[12] 吕梅，王洁英，孙大庆，等.外周血细胞比值变化在儿童传染性单核细胞增多症中的诊断价值[J]. 西安交通大学学报：医学版，2021，42（3）：460-462，483.
[13] 李瑞娜，刘小乖，雷玲侠，等.更昔洛韦治疗儿童传染性单核细胞增多症的临床疗效[J].实用临床医药杂志，2019， 23（6）：96-99.
[14] 毕晶，夏明倩，王冬萌，等.干扰素1b联合更昔洛韦治疗传染性单核细胞增多症的临床研究[J].河北医药，2019， 41（11）：1609-1613.
[15] 戴莎莎，周凯.重组人干扰素α1b辅助治疗传染性单核细胞增多症疗效的前瞻性随机对照研究[J].中国当代儿科杂志，2020，22（9）：953-957.
[16] 潘家华，杨泽玉，潘家严，等.重组人干扰素α2b口咽部喷雾治疗疱疹性咽峡炎的有效性和安全性多中心随机对照研究[J].中华实用儿科临床杂志，2020，35（4）：279-284.
[17] 王静，冯同富，杜欣，等.重组人干扰素α2b阴道泡腾胶囊联合匹多莫德治疗宫颈人乳头瘤病毒感染的临床效果[J].中国医药导报，2019，16（29）：92-95.
[18] 朱红英，鹿梦溪.标准桃金娘油肠溶胶囊联合匹多莫德治疗小儿肺炎支原体肺炎的疗效及对肺功能和免疫炎性反应的影响[J].河北医药，2019，41（1）：46-50.
[19] 颜国.匹多莫德分散片联合玉屏风颗粒对小儿反复呼吸道感染的疗效及机制研究[J].中国药物与临床，2019， 19（24）：4319-4321.
[20] 陈萍，夏训和.匹多莫德辅助治疗细菌感染性肺炎的疗效及其对患儿血清炎性因子和Th1/Th2细胞因子的影响[J].海南医学，2019，30（5）：566-568.
[21] 方彬，宫铁锋，任会利，等.甘露聚糖肽联合匹多莫德对反复呼吸道感染患者T细胞亚群、NK细胞的影响[J].药物生物技术，2019，26（4）：333-336.
[22] 孙晓慧.匹多莫德辅助应用对小儿支气管哮喘肺功能及免疫功能的影响[J].安徽医药，2019，23（2）：364-367.
[23] 杨帆，张显纯，张新.匹多莫德联合脾氨肽对呼吸道病毒感染小鼠模型γδT和Treg细胞水平以及对组织病毒载量的影响[J].中国医学装备，2020，17（6）：182-187.
[24] 周祖莲，赵通武，李玉华，等.匹多莫德对实验性免疫球蛋白A肾病大鼠肾功能及炎症反应的影响[J].中国病理生理杂志，2019，35（8）：1495-1500.
[25] 楼英萍，傅兰兰，吴蓉洲.匹多莫德联合维生素D治疗反复呼吸道感染对TLRs信号通路和炎性因子的影响[J].中华医院感染学杂志，2019，29（15）：2270-2274. |
|
|
|
